[{"id":"fdfd9de7-291d-41f6-a1e7-37009f68c58e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665739","created_at":"2021-01-19T20:43:36.156Z","updated_at":"2025-02-25T14:15:45.821Z","phase":"Phase 2","brief_title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","source_id_and_acronym":"NCT04665739","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • everolimus • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 02/03/2023","start_date":" 02/03/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"ff30d699-6a53-417a-9123-6d01ce11b0e9","acronym":"LITESPARK-005","url":"https://clinicaltrials.gov/study/NCT04195750","created_at":"2021-01-18T20:26:57.399Z","updated_at":"2025-02-25T14:07:37.008Z","phase":"Phase 3","brief_title":"A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)","source_id_and_acronym":"NCT04195750 - LITESPARK-005","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 755","initiation":"Initiation: 02/27/2020","start_date":" 02/27/2020","primary_txt":" Primary completion: 04/15/2024","primary_completion_date":" 04/15/2024","study_txt":" Completion: 09/17/2026","study_completion_date":" 09/17/2026","last_update_posted":"2025-02-17"},{"id":"2e5ccca8-120c-4e72-b9c4-3d96418121c2","acronym":"NCI-2018-01218","url":"https://clinicaltrials.gov/study/NCT03065387","created_at":"2021-01-18T15:06:02.917Z","updated_at":"2025-02-25T15:25:34.097Z","phase":"Phase 1","brief_title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","source_id_and_acronym":"NCT03065387 - NCI-2018-01218","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • KRAS • ERBB3 • ERBB4","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification","tags":["HER-2 • KRAS • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-10"},{"id":"02e83317-1e46-4ec1-8ee3-e88e0be802c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02321501","created_at":"2021-01-18T11:00:33.247Z","updated_at":"2024-07-02T16:34:27.615Z","phase":"Phase 1","brief_title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02321501","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ROS1","pipe":" | ","alterations":" ALK positive • ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Zykadia (ceritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-10"},{"id":"ca6866f9-37af-4ed6-b384-0ce5df98af8a","acronym":"NCI-2018-01284","url":"https://clinicaltrials.gov/study/NCT03008408","created_at":"2021-01-18T14:48:06.189Z","updated_at":"2024-07-02T16:35:11.704Z","phase":"Phase 2","brief_title":"A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT03008408 - NCI-2018-01284","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 08/31/2028","primary_completion_date":" 08/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-04-03"},{"id":"8e2f554f-5b71-4b80-85eb-7d4289eed34a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02456857","created_at":"2021-01-18T11:47:13.758Z","updated_at":"2024-07-02T16:35:19.566Z","phase":"Phase 2","brief_title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","source_id_and_acronym":"NCT02456857","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR • VIM","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR • VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • pegylated liposomal doxorubicin • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 01/12/2016","start_date":" 01/12/2016","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-02-13"},{"id":"ec6fbe22-b1c8-44d5-90ef-3b484be78199","acronym":"","url":"https://clinicaltrials.gov/study/NCT01827384","created_at":"2021-01-18T08:07:17.493Z","updated_at":"2024-07-02T16:35:35.234Z","phase":"Phase 2","brief_title":"MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations","source_id_and_acronym":"NCT01827384","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • carboplatin • everolimus • temozolomide • adavosertib (AZD1775) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 01/07/2014","start_date":" 01/07/2014","primary_txt":" Primary completion: 06/19/2021","primary_completion_date":" 06/19/2021","study_txt":" Completion: 10/08/2021","study_completion_date":" 10/08/2021","last_update_posted":"2023-09-29"},{"id":"0d3b1bd8-753d-4c13-8344-211ebc961613","acronym":"","url":"https://clinicaltrials.gov/study/NCT00886691","created_at":"2021-01-18T03:23:33.023Z","updated_at":"2024-07-02T16:36:17.588Z","phase":"Phase 2","brief_title":"Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT00886691","lead_sponsor":"GOG Foundation","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • everolimus"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 12/27/2010","start_date":" 12/27/2010","primary_txt":" Primary completion: 06/27/2014","primary_completion_date":" 06/27/2014","study_txt":" Completion: 03/23/2015","study_completion_date":" 03/23/2015","last_update_posted":"2022-02-04"},{"id":"ee8e4922-d012-4071-8ea1-78103b1bf080","acronym":"","url":"https://clinicaltrials.gov/study/NCT03387020","created_at":"2021-01-18T16:42:56.273Z","updated_at":"2024-07-02T16:36:25.676Z","phase":"Phase 1","brief_title":"Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors","source_id_and_acronym":"NCT03387020","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 01/13/2018","start_date":" 01/13/2018","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2021-08-27"},{"id":"8ec88316-aa95-4d1e-b522-4e36e6eaddba","acronym":"PerELISA","url":"https://clinicaltrials.gov/study/NCT02152943","created_at":"2021-01-17T17:27:27.104Z","updated_at":"2024-07-02T16:36:37.123Z","phase":"Phase 1","brief_title":"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients","source_id_and_acronym":"NCT02152943 - PerELISA","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 amplification • HER-2 mutation","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 amplification • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • everolimus • letrozole • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 07/17/2014","start_date":" 07/17/2014","primary_txt":" Primary completion: 12/14/2020","primary_completion_date":" 12/14/2020","study_txt":" Completion: 12/14/2020","study_completion_date":" 12/14/2020","last_update_posted":"2020-12-19"},{"id":"8d366e40-f175-4b50-9ec9-865b25f6b495","acronym":"","url":"https://clinicaltrials.gov/study/NCT02283658","created_at":"2021-01-18T10:45:34.418Z","updated_at":"2024-07-02T16:36:39.661Z","phase":"Phase 2","brief_title":"Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02283658","lead_sponsor":"Mayo Clinic","biomarkers":" ER • MUC16","pipe":" | ","alterations":" ER positive • MUC16 elevation","tags":["ER • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/14/2014","start_date":" 11/14/2014","primary_txt":" Primary completion: 06/15/2016","primary_completion_date":" 06/15/2016","study_txt":" Completion: 06/21/2018","study_completion_date":" 06/21/2018","last_update_posted":"2020-10-23"},{"id":"d031ad36-7a16-4af1-94b7-5eac5a77deb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00419159","created_at":"2021-01-18T01:28:30.601Z","updated_at":"2024-07-02T16:37:00.320Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy","source_id_and_acronym":"NCT00419159","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS • PTEN","pipe":"","alterations":" ","tags":["KRAS • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • oxaliplatin • irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 199","initiation":"Initiation: 12/01/2006","start_date":" 12/01/2006","primary_txt":" Primary completion: 03/01/2009","primary_completion_date":" 03/01/2009","study_txt":" Completion: 03/01/2009","study_completion_date":" 03/01/2009","last_update_posted":"2019-04-23"},{"id":"d341898e-c40c-45c0-978e-227bf3b840f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00935792","created_at":"2021-01-18T03:37:37.975Z","updated_at":"2024-07-02T16:37:17.541Z","phase":"Phase 1/2","brief_title":"Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT00935792","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD5 • CD52 • FCER2","pipe":" | ","alterations":" CD20 expression • CD52 expression","tags":["CD20 • CCND1 • CD5 • CD52 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Campath (alemtuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-09-26"}]